​
​

Y-mAbs Therapeutics (YMAB) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Y-mAbs Therapeutics Revenue Highlights

Latest Revenue (Y)

$84.82M

Latest Revenue (Q)

$18.46M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Y-mAbs Therapeutics Revenue by Period

Y-mAbs Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$84.82M29.96%
2022-12-31$65.27M87.03%
2021-12-31$34.90M68.18%
2020-12-31$20.75M100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--

Y-mAbs Therapeutics generated $84.82M in revenue during NA 2023, up 29.96% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Y-mAbs Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$18.46M-19.02%
2024-06-30$22.80M14.38%
2024-03-31$19.93M-14.69%
2023-12-31$23.36M14.22%
2023-09-30$20.45M-1.43%
2023-06-30$20.75M2.47%
2023-03-31$20.25M-35.60%
2022-12-31$31.45M150.83%
2022-09-30$12.54M16.12%
2022-06-30$10.80M2.97%
2022-03-31$10.49M9.25%
2021-12-31$9.60M7.06%
2021-09-30$8.96M-18.14%
2021-06-30$10.95M103.44%
2021-03-31$5.38M-74.06%
2020-12-31$20.75M100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31--

Y-mAbs Therapeutics generated $18.46M in revenue during Q3 2024, up -19.02% compared to the previous quarter, and up 88.96% compared to the same period a year ago.

Y-mAbs Therapeutics Revenue Breakdown

Y-mAbs Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
License$500.00K$16.00M$2.00M
Product$84.32M$49.27M$32.90M

Y-mAbs Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (99.41%), and License (0.59%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Product$18.46M$19.43M$63.57M$20.75M$16.45M$12.54M$9.80M$9.60M$8.96M$8.95M$5.38M-
License$500.00K$500.00K$15.00M-$1.00M--$2.00M----
Product, DANYELZA---$2.52M$10.49M-------

Y-mAbs Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (97.36%), and License (2.64%).

Y-mAbs Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22
Non-US$16.50M-
UNITED STATES$67.81M-
United States-$46.26M
Other countries-$3.01M

Y-mAbs Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (80.43%), and Non-US (19.57%).

Quarterly Revenue by Country

CountrySep 24Mar 24Jun 23Mar 23
Non-US$3.13M$821.00K--
UNITED STATES$15.33M$18.61M--
Non-US, Other$852.00K---
Western Europe$2.09M---
Eastern Asia$1.01M---
Latin America$1.27M---
Other countries--$4.90M$3.42M
United States--$15.85M$16.83M
CHINA--$3.54M-
Europe---$2.52M

Y-mAbs Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (64.72%), Non-US (13.22%), Western Europe (8.83%), Latin America (5.37%), Eastern Asia (4.26%), and Non-US, Other (3.60%).

Y-mAbs Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MIRMMirum Pharmaceuticals$186.37M$77.88M
STROSutro Biopharma$153.73M$25.71M
TVTXTravere Therapeutics$145.24M$62.90M
YMABY-mAbs Therapeutics$84.82M$18.46M
ARQTArcutis Biotherapeutics$59.61M$30.86M
MRUSMerus$43.95M$11.77M
MRSNMersana Therapeutics$36.85M$12.60M
VECTVectivBio$27.34M$676.00K
RVMDRevolution Medicines, Inc. Warrant$11.58M-
KRONKronos Bio$6.29M$2.37M
GBIOGeneration Bio$5.90M$4.09M
BLUEbluebird bio$3.60M$16.10M
BCELAtreca$770.00K$80.00K
BDTXBlack Diamond Therapeutics--
CCCCC4 Therapeutics--
PCVXVaxcyte--
DAWNDay One Biopharmaceuticals-$20.07M
ERASErasca--
PASGPassage Bio--
SNDXSyndax Pharmaceuticals-$12.50M
LRMRLarimar Therapeutics--
ZNTLZentalis Pharmaceuticals--
EWTXEdgewise Therapeutics--

YMAB Revenue FAQ

What is Y-mAbs Therapeutics’s yearly revenue?

Y-mAbs Therapeutics's yearly revenue for 2023 was $84.82M, representing an increase of 29.96% compared to 2022. The company's yearly revenue for 2022 was $65.27M, representing an increase of 87.03% compared to 2021. YMAB's yearly revenue for 2021 was $34.9M, representing an increase of 68.18% compared to 2020.

What is Y-mAbs Therapeutics’s quarterly revenue?

Y-mAbs Therapeutics's quarterly revenue for Q3 2024 was $18.46M, a -19.02% decrease from the previous quarter (Q2 2024), and a -9.74% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $22.8M, a 14.38% increase from the previous quarter (Q1 2024), and a 9.86% increase year-over-year (Q2 2023). YMAB's quarterly revenue for Q1 2024 was $19.93M, a -14.69% decrease from the previous quarter (Q4 2023), and a -1.58% decrease year-over-year (Q1 2023).

What is Y-mAbs Therapeutics’s revenue growth rate?

Y-mAbs Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 143.06%, and for the last 5 years (2019-2023) was 0%.

What are Y-mAbs Therapeutics’s revenue streams?

Y-mAbs Therapeutics's revenue streams in c 23 are License, and Product. License generated $500K in revenue, accounting 0.59% of the company's total revenue, down -96.88% year-over-year. Product generated $84.32M in revenue, accounting 99.41% of the company's total revenue, up 71.15% year-over-year.

What is Y-mAbs Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Y-mAbs Therapeutics was Product. This segment made a revenue of $84.32M, representing 99.41% of the company's total revenue.